

Table 4: Daily warfarin dose and clinical characteristics in patients with various *VKORC1* genotypes.

	Wild Type (1) (GG)	Heterozygous (2) (GA)	Homozygous (3) (AA)		
	Mean \pm SD median (25th-75th)	Mean \pm SD median (25th-75th)	Mean \pm SD median (25th-75th)	p Value	Multiple Comparison
Age	63.24 \pm 9.73 64 (54.5-72.5)	63.93 \pm 12.34 67 (58-73)	63.85 \pm 11.55 65 (55-75)	0.969 ^a	-
Dose	5 \pm 1.47 5 (3.93-6.07)	3.49 \pm 1.29 3.21 (2.5-4.82)	4.22 \pm 1.80 3.93 (2.5-5.44)	0.001 ^b	1-2
BMI (kg/m ²)	25.97 \pm 4.59 25 (22.89-22.79)	25.12 \pm 3.03 24.83 (22.52-27.53)	25.88 \pm 4.01 25.84 (23.07-27.68)	0.705 ^a	-
INR	2.27 \pm 0.73 2.30 (1.63-2.80)	2.43 \pm 0.79 2.4 (1.98-2.68)	2.49 \pm 0.45 2.44 (2.16-2.68)	0.410 ^b	-
Sex ^c	number (%)	number (%)	number (%)		
Female	15 (71.7%)	31 (6.7 %)	14 (21.7%)	0.745	
Male	11 (26.8%)	18 (43,9%)	12 (29.3%)		

SD: standard deviation, *VKORC1*: Vitamin K epoxide reductase genotype, *a*: one-way analysis of variance, *b*: Kruskal-Wallis Test, *c*: Chi-square test for sex, ** $p \leq 0.001$.